ReviewIndian journal of pharmacology2026
Dapsone induced hemolysis and drop in saturation in normal glucose-6-phosphate dehydrogenase level patients - alarming presentation of poor man's drug: A series of 12 cases and review of literature.
Review in Indian journal of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDapsone-induced hemolysis is well described in the literature, especially in glucose-6-phosphate dehydrogenase (G6PD) enzyme deficiency. However, it is reported rarely with normal G6PD levels.
objectivesThe objective of the study was to describe the association between dapsone and fall in oxygen saturation (SpO2) and hemoglobin after intake of the drug. MATERIALS AND
methodsAll outpatients and inpatients receiving dapsone who presented with breathlessness, fall in SpO2, hemolysis, and fall in hemoglobin were included in the study. Patients who were started on dapsone were asked to measure the SpO2 regularly and observed for any breathlessness. Complete blood count (CBC) and liver function test (LFT) were repeated, and a reticulocyte test was done after 1 week of dapsone.
resultsTwelve cases (5 female and 7 male) with a mean age of 47 years, ranging from 22 to 83 years, presented with various dermatological conditions treated with dapsone. SpO2 fell in all cases, of which eight cases developed breathlessness after starting dapsone. Nine cases developed a reduction in hemoglobin (Hb) with increased reticulocyte counts. The mean decrease in Hb was 2.74 mg/dL. LFT was deranged postdapsone in six cases. Dapsone was stopped in all cases, following which Hb level improved, and there was relief of breathlessness with normal SpO2. Confirmation was done by drug provocation with dapsone.
conclusionBaseline CBC and SpO2 with frequent repetition every week, along with reticulocyte count, are essential to look for dapsone induced hemolysis and methemoglobinemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.